Quest PharmaTech Inc Total Liabilities
Quest PharmaTech Inc total liabilities. Based on the latest financial reports, Quest PharmaTech Inc (QPT) has total liabilities worth CA$1.25 Million CAD (≈ $907.03K USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Quest PharmaTech Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Quest PharmaTech Inc (1998–2025)
Total liabilities of Quest PharmaTech Inc from 1998 to 2025. This chart illustrates how Quest PharmaTech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Quest PharmaTech Inc (QPT) long-term investment share to see how much of total assets are deployed in long-term investments.
Quest PharmaTech Inc Competitors by Total Liabilities
The table below lists competitors of Quest PharmaTech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nilsson Special Vehicles publ AB
ST:NILS
|
Sweden | Skr47.21 Million |
|
BLACK PEARL ZY-10
F:7ZX
|
Germany | €4.76 Million |
|
Stelrad Group PLC
LSE:SRAD
|
UK | GBX166.03 Million |
|
Palatin Technologies Inc
NYSE MKT:PTN
|
USA | $10.12 Million |
|
Montero Mining and Exploration Ltd
V:MON
|
Canada | CA$332.47K |
|
E Tech Resources Inc
V:REE
|
Canada | CA$1.18 Million |
|
AE Multi Holdings Bhd
KLSE:7146
|
Malaysia | RM62.93 Million |
|
UMT United Mobility Technology AG
XETRA:UMD
|
Germany | €3.32 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Quest PharmaTech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Quest PharmaTech Inc.
Liquidity & Leverage Metrics
Quest PharmaTech Inc Total Liabilities Ratios Explained
Quest PharmaTech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quest PharmaTech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quest PharmaTech Inc (1998–2025)
The table below shows the annual total liabilities of Quest PharmaTech Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | CA$1.17 Million ≈ $845.16K |
-11.67% |
| 2024-01-31 | CA$1.32 Million ≈ $956.88K |
+19.56% |
| 2023-01-31 | CA$1.11 Million ≈ $800.36K |
+77.71% |
| 2022-01-31 | CA$622.60K ≈ $450.38K |
+59.87% |
| 2021-01-31 | CA$389.44K ≈ $281.72K |
-98.14% |
| 2020-01-31 | CA$20.95 Million ≈ $15.15 Million |
+106.50% |
| 2019-01-31 | CA$10.14 Million ≈ $7.34 Million |
+1.95% |
| 2018-01-31 | CA$9.95 Million ≈ $7.20 Million |
+1256.57% |
| 2017-01-31 | CA$733.49K ≈ $530.60K |
-94.49% |
| 2016-01-31 | CA$13.30 Million ≈ $9.62 Million |
+227.17% |
| 2015-01-31 | CA$4.07 Million ≈ $2.94 Million |
+22.68% |
| 2014-01-31 | CA$3.31 Million ≈ $2.40 Million |
+95445.89% |
| 1998-01-31 | CA$3.47K ≈ $2.51K |
-- |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.